CLINICAL TRIALS PROFILE FOR COPAXONE
All Clinical Trials for Copaxone
NCT00039988 Treatment of Multiple Sclerosis With Copaxone and Albuterol Completed Autoimmunity Centers of Excellence N/A 2001-11-01 The purpose of this study is to determine the effects of glatiramer acetate (Copaxone) alone compared to Copaxone plus albuterol in patients with Multiple Sclerosis (MS). MS is thought to be an autoimmune disease of the central nervous system. Certain white blood cells of the immune system become abnormally active and mistakenly attack the myelin of nerve fibers. Myelin is a fatty sheath that surrounds nerve fibers and insulates the nerve like insulation around an electrical wire. Without proper myelin insulation, messages sent between the brain and other parts of the body may be confused or fail completely. Damage to myelin causes the symptoms of MS. The most common form of MS is known as relapsing-remitting (RR), where partial or total recovery occurs after attacks. Four therapies are currently approved for the treatment of MS. These therapies, however, are only moderately effective and can cause undesirable side effects. For this reason, there is a need to find new therapies that have minimal side effects and may stop the disease from getting worse.
NCT00039988 Treatment of Multiple Sclerosis With Copaxone and Albuterol Completed National Institute of Allergy and Infectious Diseases (NIAID) N/A 2001-11-01 The purpose of this study is to determine the effects of glatiramer acetate (Copaxone) alone compared to Copaxone plus albuterol in patients with Multiple Sclerosis (MS). MS is thought to be an autoimmune disease of the central nervous system. Certain white blood cells of the immune system become abnormally active and mistakenly attack the myelin of nerve fibers. Myelin is a fatty sheath that surrounds nerve fibers and insulates the nerve like insulation around an electrical wire. Without proper myelin insulation, messages sent between the brain and other parts of the body may be confused or fail completely. Damage to myelin causes the symptoms of MS. The most common form of MS is known as relapsing-remitting (RR), where partial or total recovery occurs after attacks. Four therapies are currently approved for the treatment of MS. These therapies, however, are only moderately effective and can cause undesirable side effects. For this reason, there is a need to find new therapies that have minimal side effects and may stop the disease from getting worse.
NCT00078338 Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis Completed Pfizer Phase 4 2004-03-01 The primary objective of the study is to assess the clinical efficacy of Rebif® 44 mcg three times per week compared with Copaxone® 20 mg daily in patients with relapsing Multiple Sclerosis.
NCT00078338 Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis Completed EMD Serono Phase 4 2004-03-01 The primary objective of the study is to assess the clinical efficacy of Rebif® 44 mcg three times per week compared with Copaxone® 20 mg daily in patients with relapsing Multiple Sclerosis.
NCT00099502 BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients Completed Bayer Phase 3 2003-11-01 The purpose of this study is to determine - whether treatment with Betaferon / Betaseron (interferon beta-1b) 500 micrograms safe, tolerable and more efficacious than treatment with interferon beta-1b 250 micrograms - whether treatment with Betaferon / Betaseron (interferon beta-1b) tolerable and more efficacious than treatment with Copaxone (Glatiramer Acetate) 20 mg
NCT00101959 Implementation Study of Treatment Optimization Recommendations on Relapsing-Remitting Multiple Sclerosis (RR MS) Subjects Withdrawn EMD Serono Phase 4 2004-11-01 Brief Summary: 800 RRMS Subjects currently treated with Avonex or Copaxone will be randomized to either continue on their current therapy or receive Rebif therapy. The subjects will be followed for 2 years. The primary objective is to compare the time to worsening to a medium level of concern as defined by the Canadian Multiple Sclerosis Working Group (CMSWG) treatment optimization recommendations.
NCT00176592 Phase IV Study, Betaseron Versus Copaxone for Relapsing Remitting or CIS Forms of MS Using Triple Dose Gad 3 T MRI Unknown status Stuart D Cook MD Phase 4 2003-01-01 This is the first comparison of efficacy of Betaseron and Copaxone for treatment of relapsing forms of MS.
Clinical Trial Conditions for Copaxone
Condition Name for Copaxone
Multiple Sclerosis 17
Relapsing Remitting Multiple Sclerosis 9
Relapsing-Remitting Multiple Sclerosis 6
Multiple Sclerosis, Relapsing-Remitting 5
Condition MeSH for Copaxone
Sclerosis 41
Multiple Sclerosis, Relapsing-Remitting 30
Syndrome 2
Clinical Trial Locations for Copaxone
Trials by Country for Copaxone
Trials by US State for Copaxone
Clinical Trial Progress for Copaxone
Clinical Trial Phase for Copaxone
Clinical Trial Status for Copaxone
Terminated 6
Clinical Trial Sponsors for Copaxone
Sponsor Name for Copaxone
Teva Pharmaceutical Industries 14
EMD Serono 3
Sanofi 3
Sponsor Type for Copaxone
BioPharmaceutical Business Intelligence